AI Article Synopsis

  • - The study aimed to evaluate the impact of pembrolizumab on survival rates for patients with advanced urothelial carcinoma (aUC) by comparing outcomes from the pre- and post-introduction periods (2003-2011 vs. 2016-2020).
  • - Researchers included 531 patients and found that those treated after pembrolizumab's introduction had significantly longer cancer-specific survival (CSS) and overall survival (OS) compared to those treated earlier.
  • - Results indicated that while recent patients treated with pembrolizumab had even better survival rates, those who did not receive the drug had similar outcomes to the earlier cohort, suggesting that pembrolizumab was a key factor in improved survival.

Article Abstract

Objectives: Although the treatment strategy for advanced urothelial carcinoma (aUC) has drastically changed since pembrolizumab was introduced in 2017, studies revealing current survival rates in aUC are lacking. This study aimed to assess (1) the improvement in survival among real-world patients with aUC after the introduction of pembrolizumab and (2) the direct survival-prolonging effect of pembrolizumab.

Methods: This multicenter retrospective study included 531 patients with aUC undergoing salvage chemotherapy, including 200 patients treated in the pre-pembrolizumab era (2003-2011; earlier era) and 331 patients treated in a recent 5-year period (2016-2020; recent era). Using propensity score matching (PSM), cancer-specific survival (CSS) and overall survival (OS) were compared between the earlier and recent eras, in addition to between the recent era, both with and without pembrolizumab use, and the earlier era.

Results: After PSM, the recent era cohort had significantly longer CSS (21 months) and OS (19 months) than the earlier era cohort (CSS and OS: 12 months). In secondary analyses using PSM, patients treated with pembrolizumab had significantly longer CSS (25 months) and OS (24 months) than those in the earlier era cohort (CSS and OS: 11 months), whereas patients who did not receive pembrolizumab in the recent era had similar outcomes (CSS and OS: 14 months) as the earlier era cohort (CSS and OS: 12 months).

Conclusions: Patients with aUC treated in the recent era exhibited significantly longer survival than those treated before the introduction of pembrolizumab. The improved survival was primarily attributable to the use of pembrolizumab.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087413PMC
http://dx.doi.org/10.1111/iju.15014DOI Listing

Publication Analysis

Top Keywords

earlier era
16
era cohort
16
introduction pembrolizumab
12
patients auc
12
patients treated
12
cohort css
12
era
10
improved survival
8
survival real-world
8
patients
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!